CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-13 | Gupta Rishi Director | Grant or award · Stock Option (right to buy) | +16,835 | 16,835 | ||
| 2024-02-13 | Derynck Mika K Director | Grant or award · Stock Option (right to buy) | +16,835 | 16,835 | ||
| 2024-02-13 | Collins Helen Louise CHIEF MEDICAL OFFICER | Grant or award · Stock Option (right to buy) | +185,000 | 185,000 | ||
| 2024-02-13 | Bauer Jake Director | Grant or award · Stock Option (right to buy) | +16,835 | 16,835 | ||
| 2024-02-13 | Ballal Rahul D. Director | Grant or award · Stock Option (right to buy) | +16,835 | 16,835 | ||
| 2024-02-06 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −4,875 | $15.11 | $74K | 12,347 |
| 2024-01-31 | 5AM Partners VI, LLC 10% owner | Sale | −417,187 | $15.00 | $6.3M | 3,888,992 |
| 2024-01-31 | 5AM Partners VI, LLC 10% owner | Sale | −82,813 | $15.00 | $1.2M | 771,983 |
| 2024-01-30 | Heyman Richard A. Director | Sale 10b5-1 | −1,270 | $16.41 | $21K | 146,010 |
| 2024-01-29 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +12,000 | $1.12 | $13K | 12,000 |
| 2024-01-29 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −12,000 | $15.85 | $190K | 0 |
| 2024-01-29 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −12,000 | 284,550 | ||
| 2024-01-29 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +3,250 | $2.48 | $8K | 3,250 |
| 2024-01-29 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,250 | $15.81 | $51K | 0 |
| 2024-01-29 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −3,250 | 245,870 | ||
| 2024-01-25 | Kintz Samuel President and CEO | Option exercise 10b5-1 | +12,000 | $1.12 | $13K | 12,000 |
| 2024-01-25 | Kintz Samuel President and CEO | Sale 10b5-1 | −2,542 | $14.94 | $38K | 9,458 |
| 2024-01-25 | Kintz Samuel President and CEO | Sale 10b5-1 | −9,458 | $15.89 | $150K | 0 |
| 2024-01-25 | Kintz Samuel President and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −12,000 | 284,550 | ||
| 2024-01-22 | Patel Anish Chief Operating Officer | Sale 10b5-1 | −4,875 | $15.14 | $74K | 17,222 |
Page 26 of 37 · 724 trades